A number of other equities research analysts also recently weighed in on OHRP. Zacks Investment Research upgraded shares of Ohr Pharmaceutical from a hold rating to a strong-buy rating and set a $3.00 price target on the stock in a research note on Friday, August 26th. Roth Capital restated a buy rating and issued a $13.00 target price on shares of Ohr Pharmaceutical in a research note on Thursday, June 16th.
Shares of Ohr Pharmaceutical (NASDAQ:OHRP) traded down 0.876% during trading on Tuesday, hitting $2.716. 7,342 shares of the stock traded hands. The company has a 50 day moving average of $2.74 and a 200-day moving average of $2.93. The company’s market cap is $87.19 million. Ohr Pharmaceutical has a 1-year low of $2.44 and a 1-year high of $6.56.
Ohr Pharmaceutical (NASDAQ:OHRP) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.03. On average, equities analysts anticipate that Ohr Pharmaceutical will post ($1.32) EPS for the current fiscal year.
Several large investors have recently modified their holdings of OHRP. BlackRock Fund Advisors increased its stake in shares of Ohr Pharmaceutical by 14.8% in the second quarter. BlackRock Fund Advisors now owns 75,333 shares of the company’s stock valued at $206,000 after buying an additional 9,685 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Ohr Pharmaceutical by 1.1% in the second quarter. Vanguard Group Inc. now owns 922,616 shares of the company’s stock valued at $2,528,000 after buying an additional 9,763 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Ohr Pharmaceutical during the second quarter valued at approximately $144,000. Bank of New York Mellon Corp increased its stake in shares of Ohr Pharmaceutical by 1.3% in the second quarter. Bank of New York Mellon Corp now owns 60,069 shares of the company’s stock valued at $164,000 after buying an additional 757 shares in the last quarter. Finally, Opaleye Management Inc. bought a new position in shares of Ohr Pharmaceutical during the first quarter valued at about $1,175,000. Institutional investors own 11.32% of the company’s stock.
Receive News & Ratings for Ohr Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.